Futura Medical Regulatory News (FUM)

Futura Medical plc

("Futura" or "the Company")

Directors' Share Dealings

Directors add to holdings after exercise of options

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that it has received notification of the following option exercises by Directors over new ordinary shares of 0.2p each in the Company, at a price of 24.25 pence per share, which took place on 10 January 2012, and of the following sales by Directors which took place on 10 January 2012 of a portion of the ordinary shares to satisfy tax obligations and option exercise costs. The Directors have retained the majority of the ordinary shares from the option exercise, thereby adding to their holdings in the Company.

·; James Barder, Chief Executive, exercised options over 200,000 ordinary shares, of which he has sold 80,000 ordinary shares in the Company at a price of 90.297 pence per share.

The Company has also received notification that Mr Barder's wife, Charlotte Barder, on 10 January 2012 gifted in aggregate 15,000 ordinary shares in the Company to their children. Mr Barder's beneficial holding in Futura remains unchanged by this gift. However for the purposes of the AIM Rules his aggregate beneficial and non-beneficial holdings (which include those of his wife) are thereby reduced by the amount of the gift.

·; David Davies, Chief Development Officer, exercised options over 200,000 ordinary shares, of which Mr Davies has sold 80,000 ordinary shares in the Company at a price of 90.297 pence per share.

·; Derek Martin, Finance Director, exercised options over 90,721 ordinary shares, of which he has sold 17,861 new ordinary shares in the Company at a price of 90.297 pence per share.

The Company has also received notification that Mr Martin on 10 January 2012 gifted 17,860 ordinary shares to his wife, Julie Martin, at no cost which have been sold on 10 January 2012 at a price of 90.297 pence per share.

The 490,721 new ordinary shares shall rank pari passu with the existing issued ordinary shares of the Company.

Following the transactions the Directors' holdings in ordinary shares in the Company for the purposes of the AIM Rules for Companies have increased to:

For the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 73,714,112 ordinary shares of 0.2p each, with one voting right per share. There are no shares held in treasury. The total number of voting rights in the Company is therefore 73,714,112.

The above figure of 73,714,112 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the Disclosure and Transparency Rules.

For any further information please contact:

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com